You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

5388 Results
Regimen
Cancer Type:
Hematologic, 
Rare Diseases, 
Sarcoma
Intent: Palliative
Funding:
ODB - General Benefit
    prednisone
Jun 2019
Document
Regimen
Intent: Adjuvant
Funding:
New Drug Funding Program
    Pembrolizumab (Adult and Pediatric) - Adjuvant Treatment for Completely Resected Stage IIB or IIC Melanoma
New Drug Funding Program
    Pembrolizumab - (Neo)adjuvant Treatment for Completely Resectable Stage III or IV Melanoma
Sep 2025
Blog post
Nausea and vomiting due to cancer treatment are two of the most dreaded side effects of chemotherapy for many patients and their care providers. The...
Jul 2019

Pages